FY2024 EPS Estimates for Cytosorbents Decreased by Analyst

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Cytosorbents in a research note issued on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings of ($0.30) per share for the year, down from their prior forecast of ($0.29). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. During the same period in the previous year, the company posted ($0.14) EPS.

A number of other equities analysts have also commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th. StockNews.com assumed coverage on shares of Cytosorbents in a report on Sunday, November 10th. They issued a “hold” rating for the company.

Cytosorbents Stock Up 2.6 %

CTSO stock opened at $0.95 on Thursday. The stock has a 50-day simple moving average of $1.13 and a two-hundred day simple moving average of $1.01. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $2.15. The firm has a market capitalization of $51.94 million, a PE ratio of -2.64 and a beta of 0.56. The company has a quick ratio of 1.71, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

A number of large investors have recently modified their holdings of the business. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter worth approximately $51,000. CM Management LLC increased its holdings in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after buying an additional 25,000 shares during the last quarter. Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after buying an additional 121,294 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.